LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

If you’re pregnant or hoping to become pregnant, it’s natural to have questions about your medications. And if you’re taking ...

GLP-1 weight-loss drugs have already taken the Europe storm, altering consumer eating habits. Even the eating habits of GLP-1 ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

The analysis also found no statistically significant difference in the risk of NAION—non-arteritic anterior ischaemic optic ...

(HealthDay News) — For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION), according ...

In this cohort study of individuals with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use was ...

The product is viewed by the CPG giant as a “one-of-a-kind opportunity” to help consumers rebuild or maintain muscle they ...

The US Food and Drug Administration’s (FDA) recent moves around GLP-1-based combination therapies are telling, not just about ...

Monday, after the company known as WeightWatchers reported better-than-expected second-quarter revenue amid robust demand for GLP-1 obesity treatments. WW, which emerged from bankruptcy on June 24, ...

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36 mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

FoodBev caught up with Rafael Acevedo, Danone’s president of yogurt, to find out more about the rising trends behind the brand's new 'first-of-its-kind' innovation.